NASDAQ : GHRS
GH Research PLC — Key statistics
Healthcare · Biotechnology · Ireland
Last price 21.5 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 1.48B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 1.41B |
| Enterprise Value | 1.04B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 68.64M |
| Shares Outstanding | 68.64M |
| Shares Change (YoY) | +12.74% |
| Shares Change (QoQ) | +7.25% |
| Owned by Insiders (%) | 24.46% |
| Owned by Institutions (%) | 43.10% |
| Float | 32.37M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 3.91 |
| P/TBV Ratio | 3.91 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 28.70 |
| Quick Ratio | 28.22 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -256.94 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -18.79% |
| Return on Assets (ROA) | -13.02% |
| Return on Invested Capital (ROIC) | -13.45% |
| Return on Capital Employed (ROCE) | -19.87% |
| Weighted Average Cost of Capital (WACC) | 11.55% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$853,014 |
| Employee Count | 73 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.33 |
| 52-Week Price Change | +43.16% |
| 50-Day Moving Average | 23.90 |
| 200-Day Moving Average | 21.57 |
| Relative Strength Index (RSI) | 46.00 |
| Average Volume (20 Days) | 335,047 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 2.01M |
| Short Previous Month | 1.76M |
| Short % of Shares Out | 2.93% |
| Short % of Float | 6.21% |
| Short Ratio (days to cover) | 6.36 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -71.43M |
| Pretax Income | -62.27M |
| Net Income | -62.27M |
| EBITDA | -71.33M |
| EBIT | -71.43M |
| Earnings Per Share (EPS) | -$0.99 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 362.65M |
| Total Debt | 360,000 |
| Net Cash | 362.29M |
| Net Cash Per Share | $5.28 |
| Equity (Book Value) | 359.49M |
| Book Value Per Share | 5.24 |
| Working Capital | 355.97M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -51.70M |
| Capital Expenditures | -138,000 |
| Depreciation & Amortization | 101,000 |
| Net Borrowing | -275,000 |
| Free Cash Flow | -51.84M |
| FCF Per Share | -$0.76 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -12.74% |
| Shareholder Yield | -12.74% |
| Earnings Yield | -4.81% |
| FCF Yield | -3.68% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $42.89 |
| Price Target Difference | 109.22% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |